Magnesium Forms & Bioavailability

Navigation

Upward Index: 02 - Compounds & Molecules MOC | Sourcing & Pricing (FI/EU): Foundational Supplements & Micronutrients - Sourcing | Literature Dossier: Magnesium Forms & Bioavailability - References

---

1. Pharmacodynamics & Mechanism of Action

Magnesium (${\text{Mg}}^{2+}$) is the second most abundant intracellular cation and acts as an obligate cofactor in over 600 enzymatic systems, including DNA/RNA polymerases, ${\text{Na}}^{+}/{\text{K}}^{+}$-ATPase pumps, and glycolytic kinases.

• Bioenergetic Chelation: Biologically active adenosine triphosphate exists predominantly as an ${\text{Mg-ATP}}^{2-}$ complex within the mitochondrial matrix and cytosol, directly governing oxidative phosphorylation and Creatine & Phosphocreatine System flux.
• Synaptic Plasticity & Neuroprotection: At resting membrane potentials, extracellular ${\text{Mg}}^{2+}$ occupies the pore of the NMDA glutamate receptor, preventing pathological ${\text{Ca}}^{2+}$ influx and excitotoxicity while upregulating NR2B-containing NMDA receptor subunits and synaptic density in the hippocampus upon selective CSF elevation.
• Autonomic & Vascular Tone: Acts as a physiological calcium-channel blocker at vascular smooth muscle L-type ${\text{Ca}}^{2+}$ channels, blunting sympathetic catecholamine release and increasing vagal heart rate variability (HRV).

---

2. Pharmacokinetics & Chelate Comparison

Intestinal absorption occurs via saturable transcellular active transport (TRPM6/TRPM7 channels in the distal small intestine) and non-saturable paracellular passive diffusion (~30–50% net absorption depending on ligand).

Chelate Form	Elemental $\text{Mg}$ (% by weight)	Oral Bioavailability	Primary Tissue Tropism & Clinical Target
Mg Bisglycinate	~14.1%	High (~40–50%)	Dipeptide-channel absorption; glycine-mediated inhibitory neurotransmission and sleep architecture
Mg L-Threonate (Magtein)	~7.2%	High (CNS-targeted)	Crosses the blood-brain barrier (BBB) via GLUT transporters; elevates CSF ${\text{Mg}}^{2+}$ by 7–15%
Mg Taurate	~8.9%	High	Cardioprotective, endothelial nitric oxide synthase (eNOS) support, and GABAergic stabilization
Mg Malate	~15.5%	High (sustained AUC)	Krebs cycle intermediate (malic acid) for skeletal muscle ATP synthesis
Mg Citrate	~16.2%	Moderate-High (~30%)	Systemic replenishment; higher osmotic draw in GI lumen at doses $>400\text{ mg}$
Mg Oxide	~60.3%	Poor (~4%)	Non-absorbable osmotic laxative; minimal systemic or intracellular uptake

---

3. Dosing, Cycling & Synergies

• Standard Protocol: $300\text{–}500\text{ mg/day}$ total elemental magnesium.
  • Cognitive / Neuroplasticity Stack: $1,500\text{–}2,000\text{ mg}$ Magnesium L-Threonate ($108\text{–}144\text{ mg}$ elemental) taken in divided doses or $60\text{ min}$ pre-sleep. Available domestically in Finland (Tier 1) following EFSA Novel Food authorization as Puhdistamo Smart Mag (Magtein® + L-Glycine) and Nutri Works Magtein Magnesium L-treonaatti via Aminopörssi.fi (https://xn--aminoprssi-jcb.fi/) and Puhdistamo.fi (see Foundational Supplements & Micronutrients - Sourcing).
  • Sleep & Parasympathetic Stack: $200\text{–}300\text{ mg}$ elemental Magnesium Bisglycinate paired with GABAergics & Anxiolytics (L-Theanine) and Amino Acids & Precursors (Glycine).
• Cycling Cadence: Non-habituating; requires continuous daily intake without washout periods.
• Synergies: Essential cofactor for 25-hydroxylase and $1\alpha$-hydroxylase conversion of Vitamin D3, K2 & Calcium Homeostasis, and S-adenosylmethionine synthetase in Methylation & B-Complex.
• Contraindications & Biomarkers to Monitor:
  • Contraindications: Severe renal insufficiency ($\text{eGFR}<30{\text{ mL/min/1.73m}}^2$), myasthenia gravis, and high-grade AV block; separate by $\ge 2\text{ hours}$ from fluoroquinolone/tetracycline antibiotics and bisphosphonates.
  • Biomarkers: RBC Magnesium (optimal: $5.5\text{–}6.5\text{ mg/dL}$; serum $\text{Mg}$ represents $<1\%$ of total body stores and masks intracellular depletion), serum creatinine/eGFR, and parathyroid hormone (PTH).

---

4. Key Scientific Evidence Summary

• Synaptic Density & Memory: Slutsky et al. (2010) demonstrated in Neuron that Magnesium L-Threonate elevated cerebrospinal fluid ${\text{Mg}}^{2+}$ by $15\%$ ($p<0.01$), upregulated hippocampal NR2B signaling, and enhanced spatial short- and long-term memory in young and aged rats.
• Human Cognitive Reversal: Liu et al. (2016) showed in a 12-week double-blind RCT ($n=44$) that $1.5\text{–}2.0\text{ g/day}$ MMFS-01 (Mg L-Threonate) improved overall cognitive composite Z-scores ($p=0.003$) and reduced functional brain age by an average of $9.4\text{ years}$.
• Bioavailability Superiority: Walker et al. (2003) and Ates et al. (2019) confirmed superior fractional absorption and tissue retention of organic chelates (citrate, glycinate, malate, acetyl-taurate) compared to inorganic magnesium oxide.

See full study breakdowns in Magnesium Forms & Bioavailability - References.